| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2006 | CN1242757C Externally applied medicine for treating andropathy and gynecopathy |
| 02/22/2006 | CN1242747C Compound baking soda injection and its preparation |
| 02/22/2006 | CN1242746C Medicine compound contg. troxeration |
| 02/22/2006 | CN1242745C Slow release (controlled releuse) preparation of doufuguosu |
| 02/22/2006 | CN1242744C Nasal cavity preparation for treating long-term allergic reaction coryza |
| 02/22/2006 | CN1242743C Method for preparing Penciclovir gelling agent |
| 02/22/2006 | CN1242742C Oryzanol containing soft capsule preparation method |
| 02/22/2006 | CN1242741C Preparation and diabetic use of gibberellins |
| 02/22/2006 | CN1242740C Mitoxantrone or mitoxantrone hydrochloride liposome injection and its preparing process |
| 02/21/2006 | US7002036 For production of (poly)peptides; comprises Michael-type addition of nucleophile to a dialkyl 2-methylidenylpropan-1,3-dioate and conversion of ester to amino moiety |
| 02/21/2006 | US7002030 Substance for lowering high cholesterol level in serum and methods for preparing and using the same |
| 02/21/2006 | US7002022 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration |
| 02/21/2006 | US7002019 aryl hydrocarbon; oxidation of 4,5-dihydro-1,3-azoles to fully unsaturated ring; heterocyclic ketones |
| 02/21/2006 | US7002018 Process for the preparation of amorphous form of torsemide |
| 02/21/2006 | US7002016 reacting 1-(phenylglyoxylyl)piperidine arenesulfonylhydrazone in dichloromethane or toluene with base and phase transfer catalyst, to form (R*,R*)-enriched 7-phenyl-1-azabicyclo[4.2.0]octan-8-one; ring opening with methanol and hydrochloric acid |
| 02/21/2006 | US7002015 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants |
| 02/21/2006 | US7002014 [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt; adjusting pH to yield the proper hydrate form |
| 02/21/2006 | US7002012 Therapeutic treatment of septic shock; chemical condensation reaction by cyclization, amidation, chemical intermediates |
| 02/21/2006 | US7002007 contacting acidic hyaluronate suspension from eggshells and acid with an anionic ion exchange medium in a buffer producing a suspension of high molecular weight hyaluronates |
| 02/21/2006 | US7002000 Nucleic acid encoding α chain of human IL-11 receptor |
| 02/21/2006 | US7001991 transferrin-doxorubicin linked with glutaraldehyde; low-toxicity, side-effect reduction |
| 02/21/2006 | US7001926 Tubulin binding agents and corresponding prodrug constructs |
| 02/21/2006 | US7001925 naphthalene or anthracene substituted triamine compounds; vectors |
| 02/21/2006 | US7001924 Inhibitors of RNase P proteins as antibacterial compounds |
| 02/21/2006 | US7001923 Taxol enhancer compounds |
| 02/21/2006 | US7001922 Peptide deformylase activated prodrugs |
| 02/21/2006 | US7001921 Cell adhesion inhibitors |
| 02/21/2006 | US7001920 Psychological disorders; antidepressant |
| 02/21/2006 | US7001919 Crystallization from solvent system |
| 02/21/2006 | US7001918 7-pyrrolyl tetracycline compounds and methods of use thereof |
| 02/21/2006 | US7001917 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents |
| 02/21/2006 | US7001916 Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
| 02/21/2006 | US7001915 Ultrashort-acting opioids for transdermal applications |
| 02/21/2006 | US7001914 Compounds |
| 02/21/2006 | US7001913 substituted naphthyridine aminopiperidines; bacterial infections |
| 02/21/2006 | US7001912 Beta-carboline hydroxamic acid substituted pyrido 3,4-B indole compounds; 9-(4-fluorobenzyl)-N-hydroxy-9H- beta -carboline-3-carboxamide |
| 02/21/2006 | US7001911 Fused cyclic modulators of nuclear hormone receptor function |
| 02/21/2006 | US7001910 substituted pyrimidinyl-amino-ethoxy benzyl-thiazolidine-diones; hypoglycemic agents |
| 02/21/2006 | US7001909 For therapy of cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease |
| 02/21/2006 | US7001908 Arylpiperazines having activity at the serotonin 1A receptor |
| 02/21/2006 | US7001907 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 02/21/2006 | US7001906 Pyrrolo (2,3-B) pyridine derivatives containing Pyran ring, useful as anticancer compounds |
| 02/21/2006 | US7001905 Substituted diarylamines as MEK inhibitors |
| 02/21/2006 | US7001904 Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases |
| 02/21/2006 | US7001903 Synergistic insecticidal mixtures |
| 02/21/2006 | US7001902 Cyclization in presence of Lawesson's reagent |
| 02/21/2006 | US7001901 Tetrazolylpropionamides as inhibitors of Aβ protein production |
| 02/21/2006 | US7001900 Central nervous system disorders |
| 02/21/2006 | US7001899 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis |
| 02/21/2006 | US7001898 Treating conditions involving increased vascular resistance and cardiac insufficiency. |
| 02/21/2006 | US7001897 Such as (1R,5S,6S)-2-(1-(4-carbamoyl-1,3-thiazol-2-yl)azetidin-3-yl)thio-6-((1R)-1 -hydroxyethyl)-1-methylcarbapen -2-em-3-carboxylic acid for treatment/prevention of bacterial infections |
| 02/21/2006 | US7001896 Side effect reduction; antidiabetic agents; using 4-diethylphosphinoylmethyl-N-(-4-bromo-2-cyanopheny)benzamide |
| 02/21/2006 | US7001895 Pyridazinones; selective inhibitors of the induced isozyme PGHS-2 (Title) and cyclooxygenase 2 (COX-2); side effect reduction; analgesics; antipyretics; antiinflamation, -arthritic and -carcinogenic agents; rheumatic diseases; |
| 02/21/2006 | US7001894 Blood flow improvers and thrombosis preventives or remedies |
| 02/21/2006 | US7001893 Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof |
| 02/21/2006 | US7001892 Pharmaceutical materials and methods for their preparation and use |
| 02/21/2006 | US7001891 Biodegradable polycation composition for delivery of an anionic macromolecule |
| 02/21/2006 | US7001890 Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
| 02/21/2006 | US7001889 Comprises praziquantel and/or pyrantel in solvent with thickener for improved bioavailability |
| 02/21/2006 | US7001888 Compositions and methods for treating cancer |
| 02/21/2006 | US7001886 Hot melt method for preparing diphenhydramine tannate |
| 02/21/2006 | US7001873 Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations |
| 02/21/2006 | US7001759 Compositions and methods for delivery of genetic material |
| 02/21/2006 | US7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 02/21/2006 | US7001621 Blends of ursolic acid/oleanolic acid |
| 02/21/2006 | US7001620 Kavalactone product |
| 02/21/2006 | US7001617 Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| 02/21/2006 | US7001612 For restoration of electrolyte balance due to sweating in the absence of strenuous physical exertion; beverages |
| 02/21/2006 | US7001611 Using astaxanthin; sleep disorders |
| 02/21/2006 | US7001607 polyaphron gel containing water-soluble fluorinated surfactant, water, and a nonpolar component, in particular, a fluorocarbon or a silicone oil; introducing gel into conjunctival sac of the eye |
| 02/21/2006 | US7001606 Biocidal polymers based on guanidine salts |
| 02/21/2006 | US7001604 Cosmetic composition |
| 02/21/2006 | US7001603 Nonaqueous hydrophilic external phase, internal oil phase, each phase being gelled by a condensation product of glycerine and a long chain fatty acid; exfoliating scrubs |
| 02/21/2006 | US7001602 Administering a neurotoxin ; therapy for enlargement of prostate gland |
| 02/21/2006 | US7001601 keyhole limpet hemocyanin (KLH) and adjuvant (QS-21; saponin derivative); immunogens; for treatment of melanomas |
| 02/21/2006 | US7001599 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory defects |
| 02/21/2006 | US7001597 Methods for altering fertility |
| 02/21/2006 | US7001589 comprises liquid core (containing hydrocarbon) and water soluble polymethylacrylamides as skins/envelopes; microencapsulation; kits |
| 02/21/2006 | US7001588 Expanded porphyrin compositions for tumor inhibition |
| 02/21/2006 | CA2453080C Polyene polyketides, processes for their production and their use as a pharmaceutical |
| 02/21/2006 | CA2423825C New perindopril salt and pharmaceutical compounds containing it |
| 02/21/2006 | CA2395196C Cyclic amp-specific phosphodiesterase inhibitors |
| 02/21/2006 | CA2356306C Sulfated phosphatidylinositols, their preparation and use |
| 02/21/2006 | CA2337846C Polymorph of ritonavir |
| 02/21/2006 | CA2308006C Topical compositions for regulating the oily/shiny appearance of skin |
| 02/21/2006 | CA2283399C Pyridazinones as inhibitors of cyclooxygenase-2 |
| 02/21/2006 | CA2267309C Use of 1-hydroxy-2-pyridones for the treatment of skin infections |
| 02/21/2006 | CA2266798C Use of at least one hydroxystilbene as an agent for reducing microorganism adherence to skin |
| 02/21/2006 | CA2259997C Remedies and preventives for stomatitis |
| 02/21/2006 | CA2251090C Phenylethanolaminotetralincarboxamide derivatives |
| 02/21/2006 | CA2250347C Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors |
| 02/21/2006 | CA2250258C Novel tetralone or benzopyranone derivatives and process for producing the same |
| 02/21/2006 | CA2220301C Osmotic device with delayed activation of drug delivery and complete drug release |
| 02/21/2006 | CA2193543C Sodium hyaluronate based ophthalmic formulation for use in eye surgery |
| 02/21/2006 | CA2187315C 4,6-di-t-butyl-2,3-dihydrobenzothiophene derivatives |
| 02/21/2006 | CA2186224C Amidino derivatives useful as nitric oxide synthase inhibitors |
| 02/21/2006 | CA2184691C L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors |
| 02/21/2006 | CA2180276C Process for isomerizing linear olefins to isoolefins |
| 02/21/2006 | CA2179931C Water-in-oil lotion containing a corticosteroid |
| 02/21/2006 | CA2175372C Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives |